We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire David Einhorn. In this article, we are going ...

Immunovant (NASDAQ:IMVT – Free Report) had its price objective decreased by Bank of America from $38.00 to $33.00 in a ...

A collaborative effort in Germany has seen an increase in efficiency of synthetic fuel synthesis propelling aviation's future ...

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Immunovant (IMVT – Research Report) yesterday and set a price target of ...

Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in ...

Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis (MG) and initial results from Period 1 of a mid-stage study of the ...

Fuels like kerosene can be produced in a climate-friendly way from CO2, water and green electricity using Power-to-Liquid ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.

Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...